“I had treatment last year and I want to give something back.”
A study looking at the changes in the breast cancer of postmenopausal women having hormone therapy (Primary Endocrine Response Study)
This study is looking at the early changes that occur in the breast cancer cells of postmenopausal women who are taking hormone therapy.
In this study the researchers want to compare samples of breast cancer tissue, before and during hormone therapy, to see if there are changes in breast cancer cells.
The aims of this study are to
- Find out what changes there are to breast cancer cells after 2 weeks of aromatase inhibitors
- Find out if these changes can be used to predict the response of breast cancer to longer term treatment
Who can enter
You can enter this trial if you
- Have breast cancer that is locally advanced
- Have breast cancer that is bigger than 2cm
- Have oestrogen receptor (ER) positive breast cancer breast cancer
- Are a
You cannot enter this trial if you
- Have breast cancer that has spread to another part of your body
This phase 3 study will recruit women from the Edinburgh Breast Unit at the Western General Hospital, Edinburgh. To start with, 40 women will be recruited so that the researchers can look for changes in breast cancer cells. Another 40 women will then be recruited to test if these changes can be used to tell in advance how breast cancer may respond to aromatase inhibitor treatment.
In this study the researchers are using an aromatase inhibitor called letrozole. All women taking part in this study will take letrozole tablets for 3 months.
The most common side effects of letrozole are
- Tiredness (fatigue)
- Hot flushes or increased sweating
- Weight gain
- Rash or itchy skin
- Loss of appetite
- Being or feeling sick
- Stomach upset
- Painful muscles, joints or bones
You can find more about letrozole on CancerHelp UK.
How to join a clinical trial
Experimental Cancer Medicine Centre (ECMC)
Lothian Health Board